Furthermore, standard chemotherapy for Sq-LC should be considered as a therapeutic option for patients with ALK-rearranged Sq-LC who harbor ALK rearrangement in FISH-positive/IHC-negative tumors and do not respond to ALK inhibitors. This evidence concerns the gene ALK and laryngotracheoesophageal cleft.